|
Market Closed -
Nasdaq Stockholm
00:00:00 19/09/2026 HKT
|
5-day change | 1st Jan Change | ||
| 1.726 SEK | -0.46% |
|
-6.60% | -12.39% |
| 09-03 | Irlab CEO Kristina Torfgaard to step down in 2027 | FW |
| 09-03 | Irlab CEO Kristina Torfgaard wants to step down | FW |
Company Valuation: IRLAB Therapeutics AB
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Market Cap 1 | 2,277 | 1,987 | 389 | 557.6 | 167.3 | 256.7 | - |
| Change | - | -12.75% | -80.42% | 43.33% | -69.99% | 53.4% | - |
| Enterprise Value (EV) | 1,875 | 1,734 | 277.7 | 494.2 | 167.3 | 256.7 | 256.7 |
| Change | - | -7.53% | -83.98% | 77.96% | -66.14% | 53.4% | 0% |
| P/E | 44x | -17.5x | -2.19x | -6.72x | - | - | - |
| PBR | - | 6.83x | - | 17.1x | - | - | - |
| PEG | - | 0x | -0x | 0.1x | - | - | - |
| Capitalization / Revenue | 11x | 32.5x | 68.5x | 5.89x | 2.91x | 2.54x | 1.79x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 2.54x | 1.79x |
| EV / EBITDA | 0x | -0x | -0x | -0x | -0x | -9.04x | 6.65x |
| EV / EBIT | 0x | -0x | -0x | -0x | -0x | -8.17x | 7.42x |
| EV / FCF | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - |
| EPS 2 | 1 | -2.19 | -3.43 | -1.6 | - | - | - |
| Distribution rate | - | - | - | - | - | - | - |
| Net sales 1 | 207.8 | 61.14 | 5.678 | 94.63 | 57.46 | 101.2 | 143.2 |
| EBITDA 1 | 56.05 | -108.3 | -176.4 | -70.53 | -89.08 | -28.4 | 38.6 |
| EBIT 1 | 52.58 | -113.1 | -180.8 | -75.11 | -93.4 | -31.4 | 34.6 |
| Net income 1 | 51.78 | -113.4 | -177.8 | -83.13 | -110 | -36.1 | 34.6 |
| Net Debt | -401.9 | -252.8 | -111.3 | -63.38 | - | - | - |
| Reference price 2 | 44.000 | 38.300 | 7.500 | 10.750 | 1.970 | 1.726 | 1.726 |
| Nbr of stocks (in thousands) | 51,748 | 51,868 | 51,868 | 51,868 | 84,938 | 148,712 | - |
| Announcement Date | 23/2/22 | 23/2/23 | 7/2/24 | 12/2/25 | 25/2/26 | - | - |
1SEK in Million2SEK
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 26.02M | |
| 32.78x | 11.92x | 24.16x | 0.6% | 1,028B | |
| 30.03x | 6.68x | 18.7x | 1.99% | 651B | |
| 33.38x | 7.81x | 16.15x | 2.6% | 466B | |
| 19.33x | 4.72x | 11.71x | 2.81% | 346B | |
| 19.72x | 5.16x | 12.79x | 3.11% | 266B | |
| 21.26x | 4.42x | 12.58x | 1.99% | 259B | |
| 24.43x | 6.42x | 11.43x | 2.62% | 208B | |
| 12.52x | 4.56x | 9.46x | 4.01% | 191B | |
| -45.4x | 6.61x | 25.81x | 2.19% | 186B | |
| Average | 16.45x | 6.48x | 15.87x | 2.44% | 360.18B | |
| Weighted average by Cap. | 23.68x | 7.73x | 17.83x | 1.99% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- IRLAB A Stock
- Valuation IRLAB Therapeutics AB
Select your edition
All financial news and data tailored to specific country editions
